APM
HOWL icon

Avidity Partners Management’s Werewolf Therapeutics HOWL Stock Holding History

Avidity Partners Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-485,000
Closed -$5.78M – 99
2021
Q4 		$5.78M Sell
485,000
-140,120
-22% -$2.11M 0.12% 75
2021
Q3 		$10.7M Sell
625,120
-25,145
-4% -$429K 0.24% 68
2021
Q2 		$11.3M Buy
+650,265
New +$8.91M 0.31% 67

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avidity Partners Management's HOWL Position: Q1 2022 in Review

Avidity Partners Management sold out of Werewolf Therapeutics (HOWL) in Q1 2022, closing a stake of 485,000 shares — an estimated $5.78M sold.

Avidity Partners Management first reported a position in HOWL in Q2 2021 and held it in 3 quarters. The position peaked at $11.3M in Q2 2021. 49 funds tracked by Wall St. Rank hold HOWL as of Q1 2022.

  • Avidity Partners Management reported no remaining Werewolf Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Avidity Partners Management sold 485,000 Werewolf Therapeutics shares in Q1 2022, an estimated $5.78M.
  • Avidity Partners Management first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 3 quarters.
  • Avidity Partners Management's Werewolf Therapeutics position peaked at $11.3M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2022.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.